JUICE Pharma Worldwide was in Chicago to report on the proceedings of the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. Medical Director Florian Brey, MD, and the JUICE team share the latest developments and research advances in cancer treatment.
Florian questions whether immunotherapy is the right approach for every patient and shares results from a recent nivolumab trial:
“Is immunotherapy the right approach for every patient? We don’t have a definitive answer to that question yet, but in today’s session on the topic we saw mostly encouraging results of immunotherapies in a range of cancers, including renal cell, hepatocellular, colorectal, and non-small cell lung cancer. What’s interesting is that the role of PD-L1 as a prognostic marker is still evolving. Both its concentration and distribution in cancerous tissues are not necessarily as predictive as we would like it to be in terms of response and outcomes.
The highlight of the session was the data readout of the CheckMate 057 trial in which nivolumab demonstrated superior overall survival in comparison to standard of care in patients with previously treated non-squamous non-small cell lung cancer by a margin of 27% risk reduction for progression or death.”